An Open-label Rollover Study to Continue ARRY-614 Treatment in Patients Previously Treated With ARRY-614 in Clinical Studies Sponsored by Array BioPharma Inc.

Trial Profile

An Open-label Rollover Study to Continue ARRY-614 Treatment in Patients Previously Treated With ARRY-614 in Clinical Studies Sponsored by Array BioPharma Inc.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs Pexmetinib (Primary)
  • Indications Leukaemia
  • Focus Therapeutic Use
  • Sponsors Array BioPharma
  • Most Recent Events

    • 03 Mar 2015 Status changed from recruiting to active, no longer recruiting according to M D Anderson Cancer centre record.
    • 30 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top